HR and breast cancer: MONARCH-3 is a randomized, double-blind, placebo-controlled, phase III study of NSAIs (anastrozole or letrozole) plus abemaciclib, or placebo in postmenopausal women with HR+/HER2− locoregionally recurrent or metastatic BC with no prior systemic therapy.